What the FDA labels say about taking them together
Meloxicam and oxaprozin
Oxaprozin's FDA label of December 26, 2024 names meloxicam in its drug interactions section; meloxicam's label does not name oxaprozin itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The oxaprozin label: “Concomitant use of oxaprozin and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the oxaprozin FDA label on DailyMed (effective December 26, 2024, Amneal Pharmaceuticals NY LLC).
What does the meloxicam label say about oxaprozin?
Meloxicam's label does not name oxaprozin itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Meloxicam label, boxed warningGastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Meloxicam label, boxed warningThis risk may occur early in treatment and may increase with duration of use (5.1) Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What does the oxaprozin label say about meloxicam?
Oxaprozin label, drug interactionsPemetrexed Clinical Impact: Concomitant use of oxaprozin and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
Source: FDA drug label (Oxaprozin, NDA217927), SOLA Pharmaceuticals, LLC, effective December 3, 2025 (SPL set 450f5941-7f10-42fe-e063-6394a90a4803), via openFDA
Source: FDA drug label (Oxaprozin), Amneal Pharmaceuticals NY LLC, effective December 26, 2024 (SPL set d9b0ca6c-4c53-4f6e-918b-02a8c472a194), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Meloxicam | Oxaprozin | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain | Osteoarthritis, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0166 per tablet 7.5 mg tablet | $0.475 per tablet 600 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once